Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Haaland, Ingvild ^a   Opsahl, Jill A ^a   Berven, Frode S ^a   Reikvam, Håkon ^a   Fredly, Hanne K ^a   Haugse, Ragnhild ^a   Thiede, Bernd ^b   McCormack, Emmet ^a,c   Lain, Sonia ^d   Bruserud, Øystein ^a,c   Gjertsen, Bjørn T ^a,c  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Acetylation; Acute myeloid leukemia; Heat shock protein; Histone; Nutlin 3; p53; SILAC

Indexed keywords

CHAPERONIN 60; GELDANAMYCIN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 40; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90ALPHA; HISTONE; HISTONE H2B; NUTLIN 3; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; STABLE ISOTOPE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; IMIDAZOLE DERIVATIVE; MACROCYCLIC LACTAM; PIPERAZINE DERIVATIVE;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DEACETYLATION; DOWN REGULATION; FLOW CYTOMETRY; HISTONE UBIQUITINATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LUNG CANCER CELL LINE; MASS SPECTROMETRY; MYELOID LEUKEMIA CELL LINE; OSTEOSARCOMA CELL LINE; UPREGULATION; WESTERN BLOTTING; WILD TYPE; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ACETYLATION; ANTINEOPLASTIC AGENTS; BENZOQUINONES; CELL LINE, TUMOR; DRUG SYNERGISM; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONES; HSP27 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMIDAZOLES; LACTAMS, MACROCYCLIC; LEUKEMIA, MYELOID, ACUTE; PIPERAZINES; PRIMARY CELL CULTURE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84901507159     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-116     Document Type: Article

References (63)

1. Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol 2011, 29:487-494. 10.1200/JCO.2010.30.1820, 21220605.
2. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115:453-474. 10.1182/blood-2009-07-235358, 19880497.
3. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848. 10.1126/science.1092472, 14704432.
4. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, Ruvolo V, Tsao T, Zeng Z, Vassilev LT, Andreeff M. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood 2005, 106:3150-3159. 10.1182/blood-2005-02-0553, 1895324, 16014563.
5. Hoe KK, Verma CS, Lane DP. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov 2014, 13:217-236. 10.1038/nrd4236, 24577402.
6. Ray-Coquard I, Blay JY, Italiano A, Le Cesne A, Penel N, Zhi J, Heil F, Rueger R, Graves B, Ding M, Geho D, Middleton SA, Vassilev LT, Nichols GL, Bui BN. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012, 13:1133-1140. 10.1016/S1470-2045(12)70474-6, 23084521.
7. Carol H, Reynolds CP, Kang MH, Keir ST, Maris JM, Gorlick R, Kolb EA, Billups CA, Geier B, Kurmasheva RT, Houghton PJ, Smith MA, Lock RB. Initial testing of the MDM2 inhibitor RG7112 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2013, 60:633-641. 10.1002/pbc.24235, 3495996, 22753001.
8. Yee K, Martinelli G, Assouline S, Kasner M, Vey N, Kelly KR, Drummond MW MD, Seiter K, Blotner S, Jukovsky L, Middleton S, Zhi J, Chen G, Zhong H, Nichols G. Phase 1b Study Of The MDM2 Antagonist RG7112 In Combination With 2 Doses/Schedules Of Cytarabine. Blood 2013, 122:498.
9. Gu L, Zhu N, Findley HW, Zhou M. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2. Leukemia 2008, 22:730-739. 10.1038/leu.2008.11, 3477706, 18273046.
10. van Leeuwen IM, Rao B, Sachweh MC, Lain S. An evaluation of small-molecule p53 activators as chemoprotectants ameliorating adverse effects of anticancer drugs in normal cells. Cell Cycle 2012, 11:1851-1861. 10.4161/cc.20254, 3372395, 22517433.
11. Lau LM, Nugent JK, Zhao X, Irwin MS. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 2008, 27:997-1003. 10.1038/sj.onc.1210707, 17700533.
12. Shin JS, Ha JH, He F, Muto Y, Ryu KS, Yoon HS, Kang S, Park SG, Park BC, Choi SU, Chi SW. Structural insights into the dual-targeting mechanism of Nutlin-3. Biochem Biophys Res Commun 2012, 420:48-53. 10.1016/j.bbrc.2012.02.113, 22402281.
13. Nicholson J, Neelagandan K, Huart AS, Ball K, Molloy MP, Hupp T. An iTRAQ proteomics screen reveals the effects of the MDM2 binding ligand Nutlin-3 on cellular proteostasis. J Proteome Res 2012, 11:5464-5478. 10.1021/pr300698d, 23039052.
14. Saddler C, Ouillette P, Kujawski L, Shangary S, Talpaz M, Kaminski M, Erba H, Shedden K, Wang S, Malek SN. Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. Blood 2008, 111:1584-1593.
15. Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H, Wang S, Malek SN. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood 2010, 116:71-80. 10.1182/blood-2010-01-261628, 2904583, 20404136.
16. Lew QJ, Tan CH, Gurumurthy M, Chu KL, Cheong N, Lane DP, Chao SH. NPMc(+) AML cell line shows differential protein expression and lower sensitivity to DNA-damaging and p53-inducing anticancer compounds. Cell Cycle 2011, 10:1978-1987. 10.4161/cc.10.12.15859, 21558800.
17. Reikvam H, Hatfield KJ, Ersvaer E, Hovland R, Skavland J, Gjertsen BT, Petersen K, Bruserud O. Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status-consequences and potentials for pharmacological intervention. Br J Haematol 2012, 156:468-480. 10.1111/j.1365-2141.2011.08960.x, 22150087.
18. Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 2008, 27:5303-5314. 10.1038/onc.2008.164, 18521084.
19. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006, 281:33030-33035. 10.1074/jbc.C600147200, 16905541.
20. Quintas-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 2011, 25:226-235. 10.1038/leu.2010.276, 21116282.
21. Reikvam H, Ersvaer E, Bruserud O. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia. Curr Cancer Drug Targets 2009, 9:761-776. 10.2174/156800909789271486, 19754360.
22. McCormack E, Haaland I, Venas G, Forthun RB, Huseby S, Gausdal G, Knappskog S, Micklem DR, Lorens JB, Bruserud O, Gjertsen BT. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia 2012, 26:910-917. 10.1038/leu.2011.315, 22064349.
23. Palani CD, Beck JF, Sonnemann J. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Invest New Drugs 2012, 30:25-36. 10.1007/s10637-010-9510-7, 20680659.
24. Vaseva AV, Yallowitz AR, Marchenko ND, Xu S, Moll UM. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors. Cell Death Dis 2011, 2:e156. 10.1038/cddis.2011.39, 3122118, 21562588.
25. Ong SE, Mann M. Stable isotope labeling by amino acids in cell culture for quantitative proteomics. Methods Mol Biol 2007, 359:37-52. 10.1007/978-1-59745-255-7_3, 17484109.
26. Jin Y, Zeng SX, Lee H, Lu H. MDM2 mediates p300/CREB-binding protein-associated factor ubiquitination and degradation. J Biol Chem 2004, 279:20035-20043. 10.1074/jbc.M309916200, 14769800.
27. Minsky N, Oren M. The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol Cell 2004, 16:631-639. 10.1016/j.molcel.2004.10.016, 15546622.
28. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007, 26:3473-3481. 10.1038/sj.onc.1210136, 17146434.
29. Xu Y, Diao Y, Qi S, Pan X, Wang Q, Xin Y, Cao X, Ruan J, Zhao Z, Luo L, Liu C, Yin Z. Phosphorylated Hsp27 activates ATM-dependent p53 signaling and mediates the resistance of MCF-7 cells to doxorubicin-induced apoptosis. Cell Signal 2013, 25:1176-1185. 10.1016/j.cellsig.2013.01.017, 23357534.
30. Peng Y, Chen L, Li C, Lu W, Chen J. Inhibition of MDM2 by hsp90 contributes to mutant p53 stabilization. J Biol Chem 2001, 276:40583-40590. 10.1074/jbc.M102817200, 11507088.
31. Walerych D, Kudla G, Gutkowska M, Wawrzynow B, Muller L, King FW, Helwak A, Boros J, Zylicz A, Zylicz M. Hsp90 chaperones wild-type p53 tumor suppressor protein. J Biol Chem 2004, 279:48836-48845. 10.1074/jbc.M407601200, 15358769.
32. Lancet JE, Gojo I, Burton M, Quinn M, Tighe SM, Kersey K, Zhong Z, Albitar MX, Bhalla K, Hannah AL, Baer MR. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 2010, 24:699-705. 10.1038/leu.2009.292, 20111068.
33. Lin K, Rockliffe N, Johnson GG, Sherrington PD, Pettitt AR. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene 2008, 27:2445-2455. 10.1038/sj.onc.1210893, 17982489.
34. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005, 4:71-78. 10.1038/nrd1609, 15688074.
35. Rodriguez MS, Desterro JM, Lain S, Lane DP, Hay RT. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol Cell Biol 2000, 20:8458-8467. 10.1128/MCB.20.22.8458-8467.2000, 102152, 11046142.
36. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell 2008, 133:612-626. 10.1016/j.cell.2008.03.025, 2914560, 18485870.
37. Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408:377-381. 10.1038/35042612, 11099047.
38. Knowell AE, Patel D, Morton DJ, Sharma P, Glymph S, Chaudhary J. Id4 dependent acetylation restores mutant-p53 transcriptional activity. Mol Cancer 2013, 12:161. 10.1186/1476-4598-12-161, 3866570, 24330748.
39. Yamaguchi H, Woods NT, Piluso LG, Lee HH, Chen J, Bhalla KN, Monteiro A, Liu X, Hung MC, Wang HG. p53 acetylation is crucial for its transcription-independent proapoptotic functions. J Biol Chem 2009, 284:11171-11183. 10.1074/jbc.M809268200, 2670122, 19265193.
40. Kim JH, Yoon EK, Chung HJ, Park SY, Hong KM, Lee CH, Lee YS, Choi K, Yang Y, Kim K, Kim IH. p53 acetylation enhances Taxol-induced apoptosis in human cancer cells. Apoptosis 2013, 18:110-120. 10.1007/s10495-012-0772-8, 23161364.
41. Quintas-Cardama A, Qui YH, Post S, Kornblau S. High p53 protein expression level independent of mutational status is an adverse prognostic factor for survival in acute myeloid leukemia. Blood 2011, 118:1490. 10.1182/blood-2011-02-339721, 3156042, 21680797.
42. Li M, Luo J, Brooks CL, Gu W. Acetylation of p53 inhibits its ubiquitination by Mdm2. J Biol Chem 2002, 277:50607-50611. 10.1074/jbc.C200578200, 12421820.
43. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, Yao TP. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. Embo J 2002, 21:6236-6245. 10.1093/emboj/cdf616, 137207, 12426395.
44. Harris CC. Protein-protein interactions for cancer therapy. Proc Natl Acad Sci U S A 2006, 103:1659-1660. 10.1073/pnas.0510948103, 1413676, 16452164.
45. Love IM, Sekaric P, Shi D, Grossman SR, Androphy EJ. The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3. Cell Cycle 2012, 11:2458-2466. 10.4161/cc.20864, 3404877, 22713239.
46. Arif M, Senapati P, Shandilya J, Kundu TK. Protein lysine acetylation in cellular function and its role in cancer manifestation. Biochim Biophys Acta 2010, 1799:702-716. 10.1016/j.bbagrm.2010.10.002, 20965294.
47. Bruserud O, Stapnes C, Tronstad KJ, Ryningen A, Anensen N, Gjertsen BT. Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML. Expert Opin Ther Targets 2006, 10:51-68. 10.1517/14728222.10.1.51, 16441228.
48. Kojima K, Konopleva M, McQueen T, O'Brien S, Plunkett W, Andreeff M. Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia. Blood 2006, 108:993-1000. 10.1182/blood-2005-12-5148, 1895860, 16543464.
49. Zhou Q, Chaerkady R, Shaw PG, Kensler TW, Pandey A, Davidson NE. Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics 2010, 10:1029-1039. 3337220, 20049865.
50. Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC, Olsen JV, Mann M. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009, 325:834-840. 10.1126/science.1175371, 19608861.
51. Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB, Yao TP. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell 2005, 18:601-607. 10.1016/j.molcel.2005.04.021, 15916966.
52. Yang Y, Rao R, Shen J, Tang Y, Fiskus W, Nechtman J, Atadja P, Bhalla K. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Res 2008, 68:4833-4842. 10.1158/0008-5472.CAN-08-0644, 2665713, 18559531.
53. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010, 10:537-549. 10.1038/nrc2887, 20651736.
54. Uo T, Veenstra TD, Morrison RS. Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms. J Neurosci 2009, 29:2824-2832. 10.1523/JNEUROSCI.6186-08.2009, 2673506, 19261878.
55. Sachweh MC, Drummond CJ, Higgins M, Campbell J, Lain S. Incompatible effects of p53 and HDAC inhibition on p21 expression and cell cycle progression. Cell Death Dis 2013, 4:e533. 10.1038/cddis.2013.61, 3613839, 23470540.
56. Schilling D, Duwel M, Molls M, Multhoff G. Radiosensitization of wildtype p53 cancer cells by the MDM2-inhibitor PXN727 is associated with altered heat shock protein 70 (Hsp70) levels. Cell Stress Chaperones 2013, 18:183-191. 10.1007/s12192-012-0369-8, 3581627, 22933182.
57. Fredly H, Reikvam H, Gjertsen BT, Bruserud O. Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. Am J Hematol 2012, 87:368-376. 10.1002/ajh.23116, 22374841.
58. Janz M, Stuhmer T, Vassilev LT, Bargou RC. Pharmacologic activation of p53-dependent and p53-independent apoptotic pathways in Hodgkin/Reed-Sternberg cells. Leukemia 2007, 21:772-779.
59. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M. Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 2007, 67:10455-10465. 10.1158/0008-5472.CAN-07-2057, 17974989.
60. Gjertsen BT, Oyan AM, Marzolf B, Hovland R, Gausdal G, Doskeland SO, Dimitrov K, Golden A, Kalland KH, Hood L, Bruserud O. Analysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses. J Hematother Stem Cell Res 2002, 11:469-481. 10.1089/15258160260090933, 12183832.
61. Anensen N, Hjelle SM, Van Belle W, Haaland I, Silden E, Bourdon JC, Hovland R, Tasken K, Knappskog S, Lonning PE, Bruserud O, Gjertsen BT. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene 2012, 31:1533-1545. 10.1038/onc.2011.348, 21860418.
62. Solstad T, Bjorgo E, Koehler CJ, Strozynski M, Torgersen KM, Tasken K, Thiede B. Quantitative proteome analysis of detergent-resistant membranes identifies the differential regulation of protein kinase C isoforms in apoptotic T cells. Proteomics 2010, 10:2758-2768. 10.1002/pmic.201000164, 20486122.
63. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008, 26:1367-1372. 10.1038/nbt.1511, 19029910.